|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||166.20 - 169.85|
|52 Week Range||144.07 - 195.81|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||20.84|
|Earnings Date||Apr 24, 2019 - Apr 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||208.32|
Qualcomm stock's more than 23% pop on the Apple patent settlement news is one for the history books. Biotech company Vertex Pharmaceuticals surged more than 21% on July 19, 2017, after successful trials. Power producer NRG Energy on July 12, 2017, announced a transformation plan to raise $2.5 billion to $4 billion by divesting 50% to 100% of its renewable energy business, sending its shares soaring.
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
CRISPR Therapeutics shares moved sharply higher after the FDA Fast Tracked the company's gene therapy targeting beta thalassemia.
CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of transfusion-dependent beta thalassemia (TDT). The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill unmet medical needs. A drug granted Fast Track Designation may be eligible for several benefits, including more frequent meetings and communications with the FDA and, if relevant criteria are met, the potential for Accelerated Approval, Priority Review or Rolling Review of a Biologics License Application (BLA).
Vertex Pharmaceuticals Incorporated (VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
With a market capitalization of US$49b, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks are their strong balance...
Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for VRTX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting VRTX. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding VRTX are favorable with net inflows of $113.22 billion. This was the highest net inflow seen over the last one-year.Error parsing the SmartText Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Editor's note: This story was previously published in June 2018. It has since been updated and republished.It's not technically summer yet, but the summer doldrums (the slowest period of the year for stocks) are on the way. There are some stocks that might just shrug off the summertime blues though. Granted, they're few and far between, but if a company is able to prove it can grow rapidly even if the economy bumps into a headwind, traders just might gravitate to these names and push them higher. * 7 High-Risk Stocks With Big Potential Rewards To that end (and in no particular order), here's a run-down of ten companies boasting outsized growth when other outfits can't exactly say the same. Some will ring a bell, and others are rather unfamiliar. In all cases though, clearly the organization is doing something right.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSource: Scott Lewis via Flickr Autodesk (ADSK)Year-to-date gain: +25%Autodesk (NASDAQ:ADSK) isn't exactly a household name. But, to users of architectural and engineering software though, Autodesk is plenty familiar. The company is the name behind a large collection of 3D modeling and computer-aided drafting platforms, most of which are sold on a subscription basis.Boring? You bet. Here's the not-boring part: Sales are projected to improve by more than 29% this year, and then accelerate to the tune of almost 27% next year. Even less boring is that such revenue growth is expected to push Autodesk out of the red and into the black.Who know cloud-based drafting software could help create one of the market's top fast-growing stocks?Source: Shutterstock Netflix, Inc. (NFLX)YTD gain: +35%Yes, Netflix (NASDAQ:NFLX) is loaded down with debt, and it doesn't seem interested in turning off the spending spigots anytime soon.A funny thing happened last quarter though. It wasn't sales growth. Revenue growth of 27% is impressive to be sure, but it wasn't particularly unusual for the streaming video platform. What was impressive was the comeback the company mounted after a disasterous Q4 in 2018. That light at the end of the tunnel may be viability after all, rather than an oncoming debt train. * 10 Medical Marijuana Stocks to Cure Your Portfolio There's still work that needs to be done. Sooner or later, somehow, the company is going to have to contain costs. The hard part of the job is done though. That's creating sales that can be converted into income, and then eventually become positive cash flow.Source: Meaghan O'Malley via Flickr (Modified) Etsy Inc (ETSY)YTD gain: +43.93%One would think an online seller of handmade crafts and one-off items would be struggling. Aside from the fact that mass production is the key to margins on most fronts, massive Amazon (NASDAQ:AMZN) is also in the same arena with its 'Handmade' sales platform.Etsy (NASDAQ:ETSY) makes it work though. Granted, it's not always been easy, for several reasons. But Etsy capitalizes on the fact that its website doesn't feel clinical or designed to blast browsers in the face with a flood of potential purchases.The numbers tell the tale. For the quarter ending in February, gross merchandise sales were up nearly 20% year-over-year, while revenue grew nearly 47%. The number of buyers and sellers grew too, confirming the company is doing something right.Source: Shutterstock Godaddy (GDDY)YTD gain: +19.35%You know the company, even if you don't remember the company. Godaddy (NYSE:GDDY) is the website hosting and website registration service perhaps best known for using television commercials featuring unusually pretty women in an overtly sexist way.The company has since outgrown the shtick. But it did put the company on the map, where it's remained. Although web-hosting and domain registration services are a dime-a-dozen industry now, Godaddy is still a first choice for many, and GoDaddy appears to have just reached an economy of scale. * 7 Biometric Stocks to Watch as AI Rises Though this year's expected 12.3% growth in sales isn't much, it's enough to beef up the bottom line. Next year's projected revenue growth of 11.2% is expected to double profits again.Source: Nvidia Nvidia (NVDA)YTD gain: +40.79%Between artificial intelligence, graphics cards and even traditional computer processors, Nvidia (NASDAQ:NVDA) has a hand in almost everything tech-related, and does quite well on all fronts.Indeed, it's become the go-to source for the burgeoning AI industry, as its hardware is the best-suited (and most available) to handle all the intensive number-crunching artificial intelligence platforms require be done.The proof of the pudding, as they say, is in the tasting. Last quarter's top line was $2.21 billion, which was no great shakes, but the mere fact of the company's recovery after last year's tech dive is is reason alone to invest.Source: Alden Chadwick Via Flickr DexCom (DXCM)YTD gain: -.02%DexCom, Inc. (NASDAQ:DXCM) makes a handful of different medical monitoring devices, but all of them focus on one thing, diabetes management. Its latest product, the Dexcom G6, takes continuous glucose monitoring to the proverbial next level.Although it is off to a rough start this year, it still is expected to grow sales nearly 20% for the next two years. * 8 Risky Stocks to Watch as Earnings Season Kicks Off That's not necessarily what makes DXCM one of the best stocks to invest in right now, however. For better or worse, the number of cases of diabetes in the United States alone could double if not triple from 2010's levels by the year 2050.Source: Svetoslav Nikolov via Flickr (Modified) Diamondback Energy (FANG)YTD gain: +9.5%The purchase of any energy-related stock right now should be thoroughly thought through. While crude prices are soaring again, demand isn't growing inordinately and the supply is increasing rather than decreasing. If you're confident enough that oil is at least going to hold steady around its current price though, Diamondback Energy Inc (NASDAQ:FANG) is an interesting name to consider.Diamondback is an independent oil and gas player, mostly focused on fracking in the Permian Basin. Unlike most peers of its ilk and size though, Diamondback is profitable -- with oil prices just above $50 per barrel.That leaves the company in a sweet spot, as evidenced by last quarter's numbers. Revenue was up 44% year-over-year, pushing the dividend up by 50%.Source: Shutterstock Weibo Corp (WB)YTD gain: +22.%It's been compared to Twitter (NYSE:TWTR), though it's not exactly an adequate comparison. Weibo (NASDAQ:WB), which operates an ad-supported microblogging site in China, has plenty of similarities to Facebook (NASDAQ:FB), as the user experience is so much more immersive.Regardless of what it's most comparable to though, Weibo posts numbers that turn heads, and is expected to keep doing so for the foreseeable future. * 10 Tech Stocks That Transformed Their Business Last quarter's revenue of $481.9 million were up 28% year-over-year, and for the year Weibo is looking for sales of between $420 million and $1.72 billion. That's well up from the year-ago top line of $427 million. Source: Images Money via Flickr (Modified) Vertex Pharmaceuticals (VRTX)YTD gain: +15.14%For the record, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) hasn't always been a red-hot growth stock, and realistically speaking it won't always be one either. Thanks to a couple of big-time recent drug approvals though, revenue is expected to grow 17% this year and grow another 26% next year.One of those drugs is cystic fibrosis drug Kalydeco. Though approved way back in 2012, it continues to win approval for new subsets of CF patients. Meanwhile, Symdeko, also for cystic fibrosis, was approved by the FDA in February.It can take a while for a drug's sales to reach full speed, especially when a company adds to its uses in the interim. Both drugs are still in high-growth modes right now though, arguably making VRTX one of the best stocks to invest in right now.Source: Shutterstock Splunk Inc (SPLK)YTD gain: +25.58%Last but not least, put Splunk Inc (NASDAQ:SPLK) on your list of fast-growing stocks to watch, if not outright buy.Don't sweat it if you haven't heard of it. Most people haven't. And even many of those who have can't really articulate what it does. To that end, the simplified version of its business model is, Splunk helps organizations gather and analyze digital data, and then actually do something useful with it. In the era of cloud computing, the Internet of Things, artificial intelligence and more, the company's proven crucial to many organizations drowning in a sea of information. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos The numbers speak for themselves. Splunk is expected to earn $1.01 per share this year, up from last year's 62 cents per share, on a 28% improvement in revenue. Next year's projected 21.6% top line growth should push profits to $1.47 per share.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Medical Marijuana Stocks to Cure Your Portfolio * 8 Best Stocks to Buy for an April Rally * Top 20 Stocks to Buy for 20-Somethings! Compare Brokers The post The 10 Fastest-Growing Stocks to Invest In Right Now appeared first on InvestorPlace.
Editor's note: This story was previously published in February 2019. It has since been updated and republished.The benefit of fast-growing stocks is self-evident, but as inflation becomes something to start worrying about, fast-growing stocks have an importance tied to timing. If you haven't noticed, there has been a lot of talk about something that we haven't heard about for almost a decade, inflation.For nearly a decade, the Federal Reserve and all the central banks in all the industrialized nations have been managing interest rates to keep them outrageously low until the financial system had a chance to right itself.InvestorPlace - Stock Market News, Stock Advice & Trading TipsNow, we're in the next phase of that great experiment. Economies are coming back online and central banks are raising interest rates to keep inflation at bay while not shutting off the green shoots of growth.But this isn't a science. It's a bit messy. It means that growth will be more uneven than it has been in the past. You need to find firms with solid sales earnings growth as well as technical and fundamental strengths to keep the profits rolling. * 10 Medical Marijuana Stocks to Cure Your Portfolio These are seven fast-growing stocks to buy today that will keep you in good stead for years to come. Kronos Worldwide (KRO)Kronos Worldwide, Inc. (NYSE: KRO) has a $1.69 billion market cap and is a very focused firm. It produces titanium dioxide (TiO2). The thing is, TiO2 has a very practical purpose that is used in a number of industries; it provides whiteness, brightness and opacity.As one of the leading providers of TiO2 in Europe and the U.S., its product is used in paints, coloring agents, plastics, rubber, silicone, ceramics, glass, the list goes on. It's a basic building block for an enormous amount of industrial and commercial applications.And as growth resumes and more products are sold, KRO will benefit by supplying a key ingredient to many of those products.Besides being one of our favorite a fast-growing stocks KRO also hands out a 5% dividend and trades at a sub-9 price-earnings ratio. Sherwin-Williams (SHW)Sherwin-Williams Co (NYSE:SHW) has sold paint and coatings now for 152 years. That's a pretty impressive record. But it's a bit unusual to see a paint company in a list of top growth stocks. Usually, it's some cloud storage firm or a breakout online retailer.However, SHW, by its size and reputation, has not only endured but it has positioned itself on top of the coatings heap. It grew from annual sales of $400,000 in 1866 to annual sales topping $15 billion last year, coming from over 100 countries around the world. * 10 Medical Marijuana Stocks to Cure Your Portfolio Its size, scope and quality is one reason hardware giant Lowe's Companies, Inc. (NYSE:LOW) inked a deal to be the only nationwide home seller to offer SHW products. This is even more exciting given that housing demand is back on track and the interest in homeowners to fixing up their current houses. Vertex (VRTX)Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the leading pharmaceuticals firms when it comes to treating cystic fibrosis (CF). That may not seem like much of a franchise given all the other more compelling diseases out there, but VRTX has built a $48 billion market cap in the sector and most of its competitors are looking for other places to find an opening.That is a big deal for pharma companies that usually are strong until patents run down or generics start eating into margins.Not so with VRTX. As new approvals keep rolling in for next-generation CF drugs, it has plenty more in the pipeline to keep this growth going. Valero Energy (VLO)Valero Energy Corporation (NYSE:VLO) is one of the top refiners in the U.S. It now has 15 oil refineries which supply 3.1 million barrels per day, and its 11 ethanol plants deliver 1.4 billion gallons of ethanol per year. Its operations now stretch across the U.S., Canada, the U.K. and Ireland.When the economy is in a growth phase, refineries are a great place to have your money. They are one of the leading economic indicators since demand for fuel is a key sign more the economy is coming back. More demand for fuel means there's more transportation of goods and services. * 10 Medical Marijuana Stocks to Cure Your Portfolio There's no doubt that refining is as cyclical as most parts of the energy sector, but when times are good, they're very good. And times are getting better every day in the energy patch. Royal Dutch Shell (RDS.A)Royal Dutch Shell (NYSE:RDS.A, NYSE:RDS.B) is one of the biggest players in the global energy markets. With a $284 billion market cap, the only Big Oil that's bigger is Exxon Mobil (NYSE:XOM). It's what is called an integrated energy company because it has operations from the fields to the pipelines to the refineries to the distribution.As with all energy firms, when times are bad, the more exposure you have to the entire production and distribution process, the tougher things get. But at the size the big oils are, they have the money to wait out the bad patches.And that's just what RDS.A has done. Now it's time to cash in. What's more, RDS.A is still delivering a mouth-watering 5.9% dividend, but that may wane as the stock price starts rising. In the meanwhile, it's easy to see why this is one of our picks for the best fast-growing stocks. Lumentum (LITE)Lumentum Holdings Inc (NASDAQ: LITE) is a specialty company that focuses on laser beams. It's one of the biggest optical and photonics companies in the world that is working on the 3D sensing sector.Essentially, 3D sensing is basically the gesture sensing that we all have become accustomed with in our mobile devices, screens in our cars, etc. It is one of the most ubiquitous aspects of our interactive age and one of the key parts of the Internet of Things (IoT) concept. * 10 Medical Marijuana Stocks to Cure Your Portfolio What's more, LITE is also a major player in the optical networking space that makes the infrastructure that makes our world "smarter," operating in as close to real time as possible. It's crucial for the next generation of cloud computing and network operations.Its laser division helps build the next generation of equipment that makes all this possible. Knight-Swift (KNX)Knight-Swift Transportation Holdings Inc (NYSE:KNX) had its humble beginnings in 1966, taking steel from the Port of Los Angeles to Arizona and bringing cotton from Arizona to LA.Today, KNX is a $5.78 billion business with 20,000 trucks on the road throughout the U.S. and Mexico. If you see a Swift logo on a truck while driving, it's a KNX truck.Charles Dow, the inspiration for the Dow Jones Industrial Average, also inspired a fundamental theory about the economy and the markets. It's simply called Dow Theory.One of the core tenants is that if you look at the transportation and the industrial sectors, you can predict how well the economy will be doing in the near future. If the transport business is rising, that's a bullish sign that the economy is on an upswing and KNX stock with it.Louis Navellier is a renowned growth investor. He is the editor of five investing newsletters: Blue Chip Growth, Emerging Growth, Ultimate Growth, Family Trust and Platinum Growth. His most popular service, Blue Chip Growth, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * 7 A-Rated Healthcare Stocks for Industry Expansion * 10 Stocks That Every 30-Year-Old Should Buy and Hold Forever Compare Brokers The post Check Out These 7 Fast-Growing Stocks to Buy Today appeared first on InvestorPlace.
The Boston area’s life science executives are playing a real-life version of musical chairs. Except in this game, there are more seats than players to fill them.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019. Mr. Wagner will report directly to Vertex Chairman, President and Chief Executive Officer Jeffrey Leiden, M.D., Ph.D., and oversee the finance, internal audit, investor relations, and global security and facilities functions. Mr. Wagner joins Vertex with deep corporate finance and health care experience, including more than a decade in public and private company CFO roles.
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
As the stock market rally weakens, sell rules are key to protect your portfolio. Our stocks to watch include Vertex and PayPal.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
Stocks surged higher Tuesday, boosted by a quick reversal in views on Federal Reserve rate policy. Dow Jones stock Nike traded in a buy range.
A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's treatment.
What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.